Levosert Shi

Levonorgestrel, the active ingredient in Levosert Shi, is a progestin presented as an intrauterine system for intrauterine use. It provides long‑acting contraception and is also indicated for the management of heavy menstrual bleeding in women of reproductive age.

GNH USA supplies Levosert Shi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing regulatory‑approved batches and supporting import documentation for global markets. All shipments adhere to WHO GMP standards and are tracked through secure logistics channels.

Levonorgestrel, delivered via an intrauterine system, is used in hormonal contraceptive and menstrual‑bleeding management pathways. - Contraception: long‑acting prevention of pregnancy for up to five years. - Heavy menstrual bleeding: reduction of menstrual blood loss and improvement of anemia. - Estrogen‑free contraception: suitable for women who have contraindications to estrogen‑containing methods.

Levosert Shi may cause a range of adverse reactions. Common side effects are usually mild and transient, while serious or rare events require prompt medical attention.

Common Side Effects: - Irregular bleeding or spotting. - Amenorrhea (absence of periods). - Abdominal or pelvic discomfort. - Breast tenderness. - Headache.

Serious or Rare Side Effects: - Pelvic inflammatory disease. - Device expulsion or malposition. - Uterine perforation during insertion. - Severe allergic reaction (e.g., rash, swelling). - Thromboembolic events (rare).

Before insertion of Levosert Shi, clinicians should observe several safety measures. - Screen for contraindications: ensure no active pelvic infection or malignancy. - Assess uterine size and shape: confirm suitability for intrauterine placement. - Avoid insertion during pregnancy: verify negative pregnancy test. - Monitor for device displacement: schedule follow‑up examinations. - Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Levonorgestrel released from an intrauterine system has limited systemic exposure, yet certain drugs can affect its efficacy.

Major Interactions (Avoid): - Enzyme inducers such as rifampin, carbamazepine, phenytoin, or St. John's wort, which may reduce hormone levels. - Antiepileptic drugs that increase hepatic metabolism of levonorgestrel.

Moderate Interactions (Monitor Closely): - Certain antibiotics (e.g., griseofulvin) that may modestly lower hormone concentrations. - Antifungal agents like ketoconazole that can alter steroid metabolism. - HIV protease inhibitors that may affect hormonal activity.